<DOC>
	<DOCNO>NCT02171715</DOCNO>
	<brief_summary>The primary objective study investigate relative bioavailability pharmacokinetics 20 mg BIBW 2992 administer film-coated immediate release tablet ( final formulation , i.e . phase III/to-be-marketed formulation ) healthy subject comparison drink solution comparison trial formulation II tablet , administer phase II clinical trial also partly phase I trial .</brief_summary>
	<brief_title>BIBW 2992 Administered Tablet ( Final Formulation ) Compared BIBW 2992 Drinking Solution BIBW 2992 Tablet ( Trial Formulation II ) Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male accord complete medical history , include physical examination , vital sign ( BP ( blood pressure ) , PR ( pulse rate ) ) , 12lead ECG ( electrocardiogram ) , clinical laboratory test Age 21 55 year , inclusive Body mass index 18.5 29.9 kg/m2 , inclusive Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include drug allergy excipients ) Intake drug long halflife ( &gt; 24 hour ) within one month prior administration trial drug trial Use drug ( include herbal preparation , vitamin nutrient supplement ) within 10 day prior first administration trial drug trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke within inhouse period 12 hour 25 hour administration trial drug Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial drug trial ) Excessive physical activity ( within one week prior administration trial drug trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsades de Points , e.g. , heart failure , hypokalemia , family history Long QT Syndrome Exclusion criterion specific study : Total bilirubin great 1.5 mg/dL History clinically relevant skin disease , psoriasis moderate/severe acne Female gender Male subject refuse minimise risk female partner become pregnant first dose day 3 month completion study . Acceptable method contraception male volunteer include vasectomy less 3 month prior dose , barrier contraception another medically accept contraceptive method . For female partner male volunteer , acceptable method contraception include intrauterine device , tubal ligation , hormonal contraceptive least two month , diaphragm spermicide</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>